[go: up one dir, main page]

NO20062496L - Fremgangsmater for behandling av astma - Google Patents

Fremgangsmater for behandling av astma

Info

Publication number
NO20062496L
NO20062496L NO20062496A NO20062496A NO20062496L NO 20062496 L NO20062496 L NO 20062496L NO 20062496 A NO20062496 A NO 20062496A NO 20062496 A NO20062496 A NO 20062496A NO 20062496 L NO20062496 L NO 20062496L
Authority
NO
Norway
Prior art keywords
pkc
methods
protein
agents
inhibit
Prior art date
Application number
NO20062496A
Other languages
English (en)
Inventor
Divya Chaudhary
Cara Williams
Marion Kasaian
Suzana Marusic
Robert Czerwinski
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20062496L publication Critical patent/NO20062496L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Fremgangsmåter som er anvendelige for behandling av astma er beskrevet. Fremgangsmåtene innbefatter screening med henblikk på midler som hemmer dannelsen av et PKC-?-protein, samt midler som hemmer kinaseaktiviteten av et PKC-?-protein eller et funksjonelt fragment derav, hvor slike midler er anvendelige for behandling av astma. Fremgangsmåtene innbefatter også screening med henblikk på midler som hemmer dannelsen av et rapportørgenprodukt som kodes for av en nukleinsyresekvens som er operabelt bundet til en PKC-?-promoter. Det er også beskrevet fremgangsmåter for behandling av astma, som innbefatter administrering av et middel som hemmer dannelsen av et funksjonelt PKC-?-protein eller kinaseaktiviteten av et PKC-?-protein eller et funksjonelt fragment derav. En isolert mastcelle som mangler ekspresjon av endogen PKC-?, er også beskrevet.
NO20062496A 2003-12-24 2006-05-31 Fremgangsmater for behandling av astma NO20062496L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53252503P 2003-12-24 2003-12-24
US58941504P 2004-07-20 2004-07-20
PCT/US2004/043281 WO2005062918A2 (en) 2003-12-24 2004-12-22 Methods of treating asthma

Publications (1)

Publication Number Publication Date
NO20062496L true NO20062496L (no) 2006-09-11

Family

ID=34743021

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062496A NO20062496L (no) 2003-12-24 2006-05-31 Fremgangsmater for behandling av astma

Country Status (14)

Country Link
US (1) US20050164323A1 (no)
EP (1) EP1702214A4 (no)
JP (1) JP2007525210A (no)
KR (1) KR20060127415A (no)
AU (1) AU2004308441A1 (no)
BR (1) BRPI0417212A (no)
CA (1) CA2545722A1 (no)
CR (1) CR8398A (no)
EC (1) ECSP066672A (no)
IL (1) IL175351A0 (no)
MX (1) MXPA06007094A (no)
NO (1) NO20062496L (no)
RU (1) RU2006126704A (no)
WO (1) WO2005062918A2 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
CA2535029C (en) 2003-08-07 2013-07-16 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
DE102005020754B3 (de) * 2005-05-02 2007-01-11 Altana Pharma Ag Zelluläres Assayverfahren zur Identifizierung von PKCtheta-Inhibitoren
CA2625674C (en) * 2005-08-29 2015-04-14 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
GB0617222D0 (en) * 2006-08-31 2006-10-11 Vereniging Het Nl Kanker I Antibiotics
JP5319549B2 (ja) 2006-12-29 2013-10-16 アボット・ラボラトリーズ 溶液内捕捉イムノアッセイで使用する非変性細胞溶解試薬
EP2118654B1 (en) * 2006-12-29 2013-03-27 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
JP4968611B2 (ja) * 2006-12-29 2012-07-04 アボット・ラボラトリーズ 免疫抑制剤の改善された測定法
US7914999B2 (en) * 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
WO2008091814A2 (en) * 2007-01-22 2008-07-31 Wyeth Assessment of asthma and allergen-dependent gene expression
CA2685123A1 (en) * 2007-04-23 2008-10-30 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
US20100310542A1 (en) * 2007-07-30 2010-12-09 Healor Ltd. Pharmaceutical Compositions for treating wouds and related methods
WO2010017473A2 (en) * 2008-08-07 2010-02-11 The Salk Institute For Biological Studies Method of identifying ikk2 activators or inhibitors
JP5781943B2 (ja) 2009-01-21 2015-09-24 ライジェル ファーマシューティカルズ， インコーポレイテッド 炎症性疾患、自己免疫疾患または増殖性疾患の治療に有用なｎ２−（３−ピリジルまたはフェニル）−ｎ４−（４−ピペリジル）−２，４−ピリミジンジアミン誘導体
US20110130415A1 (en) 2009-12-01 2011-06-02 Rajinder Singh Protein kinase c inhibitors and uses thereof
WO2012012619A1 (en) 2010-07-21 2012-01-26 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
RU2526146C2 (ru) * 2012-09-27 2014-08-20 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Способ профилактики и лечения бронхиальной астмы, осложняющих ее респираторных вирусных инфекций и других воспалительных заболеваний дыхательных путей
WO2014089112A1 (en) 2012-12-04 2014-06-12 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
WO2014151900A1 (en) 2013-03-14 2014-09-25 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2150470A1 (en) * 1992-11-30 1994-06-09 S.P.I. Synthetic Peptides Incorporated Polyunsaturated fatty acyl-peptide composition
US5776716A (en) * 1994-02-01 1998-07-07 Terrapin Technologies, Inc. Methods for identifying agents which block the interaction of fyn with PKC-theta, and uses thereof
US5935803A (en) * 1994-02-01 1999-08-10 Terrapin Technologies, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
US6054286A (en) * 1996-06-18 2000-04-25 Telik, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
US6040152A (en) * 1996-12-31 2000-03-21 National Jewish Medical And Research Center Method and assay for regulation of T cell proliferation
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
EP1115847A1 (en) * 1998-09-25 2001-07-18 Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
WO2000036083A2 (en) * 1998-12-17 2000-06-22 La Jolla Institute For Allergy And Immunology Pkc-interacting cousin of trx (picot) polypeptides, polynucleotides, and methods of making and using them
SE9902387D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New pharmaceutically active compounds
US6190869B1 (en) * 1999-10-26 2001-02-20 Isis Pharmaceuticals, Inc. Antisense inhibition of protein kinase C-theta expression
US20020068271A1 (en) * 1999-12-27 2002-06-06 Amnon Altman Methods for identifying agents capable of modulating protein kinase C theta (PKC0) activity

Also Published As

Publication number Publication date
WO2005062918A2 (en) 2005-07-14
AU2004308441A1 (en) 2005-07-14
CA2545722A1 (en) 2005-07-14
JP2007525210A (ja) 2007-09-06
BRPI0417212A (pt) 2007-02-06
CR8398A (es) 2006-10-06
WO2005062918A3 (en) 2005-08-25
KR20060127415A (ko) 2006-12-12
ECSP066672A (es) 2006-10-25
IL175351A0 (en) 2006-09-05
EP1702214A4 (en) 2007-12-19
RU2006126704A (ru) 2008-01-27
MXPA06007094A (es) 2006-08-23
US20050164323A1 (en) 2005-07-28
EP1702214A2 (en) 2006-09-20

Similar Documents

Publication Publication Date Title
NO20062496L (no) Fremgangsmater for behandling av astma
Geremia et al. Activation of Akt–mTORC1 signalling reverts cancer‐dependent muscle wasting
Cortellino et al. The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity
Singh Mitochondria damage checkpoint, aging, and cancer
Robin et al. SORBS2 transcription is activated by telomere position effect–over long distance upon telomere shortening in muscle cells from patients with facioscapulohumeral dystrophy
Plant et al. Absence of caspase-3 protects against denervation-induced skeletal muscle atrophy
NO20082476L (no) Bicykliske forbindelser med kinaseinhiberende aktivitet
NO20092651L (no) Dihydropyridinderivater som er anvendelige som proteinkinaseinhibitorer
WO2005030121A3 (en) Compounds, compositions and methods
KR20140019770A (ko) 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
WO2002031134A3 (en) Novel serine protease genes related to dppiv
DK1474406T3 (da) Disubstituerede thiazolylcarboxanilider samt deres anvendelse som mikrobicider
Tossidou et al. SUMOylation determines turnover and localization of nephrin at the plasma membrane
US11236341B2 (en) RNA aptamers against transferrin receptor (TFR)
WO2007034221A3 (en) Non small cell lung cancer therapy prognosis and target
WO2007065010A3 (en) Anti-angiogenesis compounds
NO20053112L (no) Peptider som malsoker tumor- og endotelceller, sammensetninger og anvendelser av slike.
Ma et al. LKB1 inhibits the proliferation of gastric cancer cells by suppressing the nuclear translocation of Yap and β-catenin
DK1590467T3 (da) Anvendelse af regulatoriske sekvenser til specifik, transient ekspression i neuronalt bestemte celler
Riffo-Campos et al. Role of epigenetic factors in the selection of the alternative splicing isoforms of human KRAS in colorectal cancer cell lines
DE60333901D1 (de) Verfahren zur reduzierung der angiogenese
BR112021026531A2 (pt) Composto, composição farmacêutica, e, método para prevenir ou tratar uma doença mediada pela tirosina cinase 2
Urban et al. Distinct functions of human RecQ helicases during DNA replication
Hu et al. Synthesis of 8-hydroxy-2-iminochromene derivatives as selective and potent inhibitors of human carbonyl reductase 1
Drew et al. Ageing and subcellular distribution of mitochondria: role of mitochondrial DNA deletions and energy production

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application